Does folic acid use decrease the risk for spina bifida after in utero exposure to valproic acid?

Women with child wish are advised to take folic acid supplements to reduce the risk for spina bifida. However, there is less evidence for this protective effect in women using valproic acid (VPA). We investigated the effect of folic acid in women exposed to VPA in the first trimester of pregnancy.

[1]  L. de Jong-van den Berg,et al.  Additional information from parental questionnaires and pharmacy records for registration of birth defects , 2004, European Journal of Epidemiology.

[2]  M. A. Mansoor,et al.  Antiepileptic drugs as independent predictors of plasma total homocysteine levels , 2001, Epilepsy Research.

[3]  Jane A. Evans,et al.  Reduction in neural-tube defects after folic acid fortification in Canada. , 2007, The New England journal of medicine.

[4]  Brentlinger Pe.  Folic acid antagonists during pregnancy and risk of birth defects. , 2001 .

[5]  H. Nau,et al.  Methotrexate increases valproic acid-induced developmental toxicity, in particular neural tube defects in mice. , 1992, Teratogenesis, carcinogenesis, and mutagenesis.

[6]  J. Morrow,et al.  Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate , 1999, Seizure.

[7]  H. Nau,et al.  Methionine reduces the valproic acid-induced spina bifida rate in mice without altering valproic acid kinetics. , 1996, The Journal of nutrition.

[8]  D. Chitayat,et al.  Evidence for multi-site closure of the neural tube in humans. , 1993, American journal of medical genetics.

[9]  Z. Kostrouch,et al.  Valproic acid, a molecular lead to multiple regulatory pathways. , 2007, Folia biologica.

[10]  W. Hauser,et al.  Management issues for women with epilepsy—Focus on pregnancy (an evidence‐based review): II. Teratogenesis and perinatal outcomes , 2009, Epilepsia.

[11]  G. Varela-Moreiras,et al.  Acute valproate administration impairs methionine metabolism in rats. , 2002, The Journal of nutrition.

[12]  P. Gros,et al.  Toward understanding the genetic basis of neural tube defects , 2007, Clinical genetics.

[13]  S. Dial,et al.  Effect of supplemental folic acid on valproic acid-induced embryotoxicity and tissue zinc levels in vivo. , 1995, Teratology.

[14]  H. Nau,et al.  Effect of supplementation with folinic acid, vitamin B6, and vitamin B12 on valproic acid-induced teratogenesis in mice. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[15]  T. Einarson,et al.  Prenatal Multivitamin Supplementation and Rates of Congenital Anomalies: a Meta-analysis , 2022 .

[16]  Í. Lopes-Cendes,et al.  Repeated Neural Tube Defects and Valproate Monotherapy Suggest a Pharmacogenetic Abnormality , 2001, Epilepsia.

[17]  C. D'Giano,et al.  Major malformations in offspring of women with epilepsy. , 2003, Neurology.

[18]  H. Nau,et al.  Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanism of teratogenesis. , 1992, Neurology.

[19]  J. Ray.  Folic acid food fortification in Canada. , 2004, Nutrition reviews.

[20]  W. Hauser,et al.  Management issues for women with epilepsy—Focus on pregnancy (an evidence‐based review): III. Vitamin K, folic acid, blood levels, and breast‐feeding , 2009, Epilepsia.

[21]  F. Essien,et al.  Methionine but not folinic acid or vitamin B-12 alters the frequency of neural tube defects in Axd mutant mice. , 1993, The Journal of nutrition.

[22]  M. Yerby.  Teratogenicity and antiepileptic drugs: potential mechanisms. , 2008, International review of neurobiology.

[23]  N. Greene,et al.  Mouse models of neural tube defects: Investigating preventive mechanisms , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[24]  K. Shiota,et al.  Neural tube closure in humans initiates at multiple sites: evidence from human embryos and implications for the pathogenesis of neural tube defects , 2000, Anatomy and Embryology.

[25]  M. Cornel,et al.  De geschiedenis van de registratie en frequentiebewaking van aangeboren afwijkingen in Nederland , 2008 .

[26]  T. Kishi,et al.  Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy , 1997, Journal of the Neurological Sciences.

[27]  G. Baker,et al.  The effectiveness of preconception counseling to reduce adverse pregnancy outcome in women with epilepsy: What’s the evidence? , 2009, Epilepsy & Behavior.

[28]  E. Van Obberghen,et al.  Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a neural tube defect. , 2007, Birth defects research. Part A, Clinical and molecular teratology.

[29]  H. Nau,et al.  VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione. , 1998, Teratogenesis, carcinogenesis, and mutagenesis.

[30]  B. Irwin,et al.  Folic acid use and major congenital malformations in offspring of women with epilepsy: a prospective study from the UK Epilepsy and Pregnancy Register , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[31]  M. Yerby.  Chapter 10 Teratogenicity and Antiepileptic Drugs , 2008 .

[32]  H. Nau,et al.  Valproic acid-induced neural tube defects: reduction by folinic acid in the mouse. , 1987, Life sciences.

[33]  K. Meador,et al.  Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. , 2009, The New England journal of medicine.

[34]  M. Schwaninger,et al.  Elevated Plasma Concentrations of Homocysteine in Antiepileptic Drug Treatment , 1999, Epilepsia.

[35]  M. Martinez-frias,et al.  Folic acid: a public-health challenge , 2006, The Lancet.